Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
-
Upload
griselda-craig -
Category
Documents
-
view
212 -
download
0
Transcript of Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
![Page 1: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/1.jpg)
Parkinson’s Disease and Treatment
Shalla HansonMedicinal Chemistry April 2009
![Page 2: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/2.jpg)
Description of Disease
• Parkinson’s disease (PD) is typically considered a chronic, progressive neurodegenerative movement disorder. However, it is now known to have variety of nonmotor symptoms as well.
![Page 3: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/3.jpg)
Major Symptoms-TRAP• Tremor• Rigidity • Akinesia/Bradykinesia• Postural InstabilityOther motor symptoms include:• Gait• Dystonia• Hypophonia• Drooling• Dysphagia• Fatigue • Akathesia
![Page 4: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/4.jpg)
Nonmotor Symptoms• Mood—20-80% suffer from depression.• Behavior—indirectly, e.g., a result of dementia, depression.• Thinking-slowed reaction time and executive dysfunction• Sensation—impaired sense of smell• Excessive daytime sleep, insomnia, and REM sleep
disturbances.• Vision problems• Impaired proprioception• Oily skin• Weight loss• Incontinence• Constipation• Drooling
![Page 5: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/5.jpg)
Primary Known Causes
• Idiopathic—majority of cases• Genetic• Drug induced—Calcium Channel Blockers• Toxins—Supported by the geographically
varied incidence• Head Trauma• Cerebral Anoxia
![Page 6: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/6.jpg)
Pathophysiology
• Decreased stimulation of the motor cortex by the basal ganglia, usually due to the inadequate production and action of dopamine (produced in the dopaminergic neurons of the brain.)
• The specific region affected seems to be the pars compacta in the substantia nigra where there is a marked loss in dopaminergic cells.
• We also see a considerably high activity in the cells of the Subthalamic nucleus, which inhibits movement.
• High presence of Lewy bodies in dopaminergic cells.
![Page 7: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/7.jpg)
Diagnosis
• PET Scan—decreased dopaminergic activity in the substantia nigra
• Unified Parkinsons Disease Rating Scale—cognitive interview
• Normal CT• Normal MRI
![Page 8: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/8.jpg)
History• PD was first described in detail by James Parkinson in 1817
in “An Essay on the Shaking Palsey.”• Carlsson in 1950, determined that dopamine was a
neurotransmitter and was exceptionally concentrated in the basal ganglia.
• Carlsson’s research later showed that Reserpine demonstrates a correlation between motor impairment and decreased dopamine levels. L-Dopa also given to animals which alleviated symptoms and initiated medicinal therapies for PD in 1967.
• In California in 1980 a group of opiate addicts consumed MPTP N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and revealed a pro-toxin, allowing another animal model of PD.
![Page 9: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/9.jpg)
Treatment
• Education• Exercise• Nutrition• Psychiatric counseling
![Page 10: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/10.jpg)
Treatment
• Oral Medication– L-Dopa (aka Levodopa)– Most popular treatment– Form of dopamine which
is able to cross the BBB through transport in L-AA system and can then be metabolized to dopamine.
– Sinemet = levodopa + carbidopa
![Page 11: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/11.jpg)
Treatment• Oral Medications– MAO-B Inhibitors– Selegiline = most common
• Dopamine Agonists– Ropinirole– Apomorphine– Lisuride
• COMT Inhibitors (Catachol-O-methyl transferase Inh.)– Tolcapone– Entacapone– Stalevo = levodopa, carbadopa, and entacapone
![Page 12: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/12.jpg)
Treatment
• Surgical Procedures – Deep Brain
Stimulation – Creating a lesion in
the subthalamic nucleus or globus pallidus
![Page 13: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/13.jpg)
Current Research
• Gene Therapy– GAD = Glutamic Acid Decarboxylase
• Deep Brain Stimulation– Controlled Impulses– Pallidotomy-not enough data to assess results well– Subthalotomy—improvements in contralateral rigidity– Subthalamic Deep Brain Stimulation—mimics
Levodopa
![Page 14: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/14.jpg)
Works CitedBritton, Thomas C. "NONMOTOR ASPECTS OF PARKINSON'S DISEASE."
Current Medical Literature: Neurology 20 (2004): 45-50."Parkinson's Disease." Current Medical Literature: Neurology 23
(2007): 44-48.Marceglia, Sara, and Alberto Priori. "Sex, genes, hormones and nigral
neurodegeneration: two different Parkinson's diseases in males and in females." Future Neurology 2 (2007): 499-503.
"Literature Review: Pathophysiology." Current Medical Literature: Parkinson's Disease 5 (2003): 59-61.
"Literature Review: Medical Treatment." Current Medical Literature: Parkinson's Disease 5 (2003): 66-70.
"Literature Review: Surgical Treatment." Current Medical Literature: Parkinson's Disease 5 (2003): 71-72.
![Page 15: Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.](https://reader036.fdocuments.us/reader036/viewer/2022083004/56649db05503460f94a9ea89/html5/thumbnails/15.jpg)